| Hughes, Derralynn |
| Active, not recruiting | 1/2 | 34 | Europe, Canada, US, RoW | ST-920 | Sangamo Therapeutics | Fabry Disease | 04/25 | 09/25 | | |
NCT05487599: A Clinical Trial of PR001 (LY3884961) in Patients with Peripheral Manifestations of Gaucher Disease (PROCEED) |
|
|
| Recruiting | 1/2 | 15 | Europe, US | LY3884961 | Prevail Therapeutics, Eli Lilly and Company | Gaucher Disease, Gaucher Disease, Type 1 | 10/30 | 10/30 | | |
| Active, not recruiting | 1 | 18 | Europe, US, RoW | FLT201 | Freeline Therapeutics, Freeline Therapeutics Limited | Gaucher Disease, Type 1 | 12/24 | 01/25 | | |
RaILRoAD, NCT03305250: Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease |
|
|
| Active, not recruiting | N/A | 169 | Europe, RoW | Implantable Loop Recorder | University Hospital Birmingham NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, University of Sydney, Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, Sheffield Teaching Hospitals NHS Foundation Trust | Fabry Disease | 07/26 | 07/27 | | |
| Recruiting | N/A | 100 | Europe | Wearable technology monitoring | Royal Free Hospital NHS Foundation Trust, Brunel University | Fabry Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 250 | Europe | Stratified response to Enzyme Therapy, Stratified response to Substrate Reduction Therapy, Splenectormy | Cambridge University Hospitals NHS Foundation Trust, Medical Research Council, National Institute for Health Research, United Kingdom | Gaucher Disease, Type I, Gaucher Disease, Type III | 09/28 | 12/28 | | |
| Mandal, Swapna |
| Completed | N/A | 120 | Europe | The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA), Positional Therapy | Royal Brompton & Harefield NHS Foundation Trust, National Institute for Health Research, United Kingdom, University of Oxford | Sleep Apnea, Obstructive, Positional Sleep Apnea | 03/23 | 03/23 | | |
NCT04495062: The Use of Wearable Technology to Acquire Signals for COPD Research |
|
|
| Completed | N/A | 63 | Europe | | Royal Free Hospital NHS Foundation Trust, Imperial College London, Acurable Ltd. | Pulmonary Disease, Chronic Obstructive | 08/23 | 08/23 | | |
NCT05167201: Domiciliary Nasal High Flow and Patient Outcomes in Chronic Hypercapnic Respiratory Failure in the United Kingdom |
|
|
| Active, not recruiting | N/A | 54 | Europe | Nasal High Flow | Royal Free Hospital NHS Foundation Trust, Fisher and Paykel Healthcare, Royal Free Charity | Chronic Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome (OHS), Nasal High Flow, Health-related Quality of Life | 01/24 | 01/24 | | |
NCT06097949: AcuPebble to Remotely Monitor Patients With OSA on CPAP Therapy |
|
|
| Recruiting | N/A | 25 | Europe | AcuPebble SA100 | Royal Free Hospital NHS Foundation Trust, Acurable Ltd. | Sleep Apnea, Obstructive | 02/24 | 02/24 | | |
| Goldstein, Robert |
| Active, not recruiting | 3 | 308 | Europe, Japan, US, RoW | carboplatin, paclitaxel, retifanlimab, INCMGA00012 | Incyte Corporation | Squamous Cell Carcinoma of the Anal Canal | 04/24 | 03/26 | | |
|
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Recruiting | N/A | 6000 | Europe | | The Christie NHS Foundation Trust | Cancer | 01/26 | 01/28 | | |
| Denton, Christopher |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
| Active, not recruiting | 2 | 120 | Europe | Mycophenolate Mofetil 500mg | University College, London, Versus Arthritis | Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis | 11/23 | 04/24 | | |
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery |
|
|
| Recruiting | 3 | 90 | Europe | CSL511 Fibrinogen concentrate (human), Cryoprecipitate | CSL Behring | Acquired Fibrinogen Deficiency | 09/26 | 10/26 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation |
|
|
| Active, not recruiting | 2 | 100 | RoW | Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032 | Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU | Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers | 07/15 | 05/18 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Completed | 1 | 47 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 01/25 | 01/25 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors |
|
|
| Withdrawn | 1 | 10 | RoW | Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib | Center Trials & Treatment, BioGene Pharmaceutical | Advanced or Recurrent Solid Tumors, Breast Neoplasm | 12/23 | 01/24 | | |
|
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Terminated | 1 | 1 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus |
|
|
| Terminated | N/A | 2432 | US, RoW | | Center Trials & Treatment, Oleg Martynenko | COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE) | 03/23 | 03/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 09/25 | 09/25 | | |
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant |
|
|
| Recruiting | N/A | 200 | RoW | Gilteritinib, ASP2215, XOSPATA® | Astellas Pharma Singapore Pte. Ltd. | Acute Myeloid Leukemia | 06/25 | 06/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Recruiting | N/A | 350 | US | Veye Lung nodules | Aidence | Lung; Node | 07/21 | 07/21 | | |
| Manager, Project |
| Recruiting | 3 | 200 | Canada | Magnesium sulfate and then Digoxin, Amiodarone | Sunnybrook Health Sciences Centre, Sunnybrook Research Institute | Atrial Fibrillation New Onset | 10/25 | 04/26 | | |
| Recruiting | 3 | 4514 | US | nasal antimicrobial photodisinfection therapy | Ondine Biomedical Inc. | Surgical Site Infections, Surgical Wound Infection, Infections, Anti-Infective Agents | 07/25 | 08/25 | | |
| Recruiting | 2 | 81 | Europe, US, RoW | Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda | Flamingo Therapeutics NV | HNSCC | 05/25 | 05/26 | | |
NCT05714657: Shortened Course Adjuvant Radiotherapy Following TORS |
|
|
| Recruiting | 2 | 104 | US | Shortened Course Adjuvant Radiotherapy Following TORS | Abramson Cancer Center at Penn Medicine | HPV-Associated Oropharyngeal Squamous Cell Carcinoma | 12/25 | 04/26 | | |
| Recruiting | 2 | 30 | US | Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost | Abramson Cancer Center at Penn Medicine | Prostate Cancer | 01/26 | 12/31 | | |
| Recruiting | 2 | 25 | US | Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) | Abramson Cancer Center at Penn Medicine | Cervical Cancer, Uterine Cancer, Endometrial Cancer | 05/26 | 11/26 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
| Completed | 1/2 | 116 | Europe | DMX-1002, Ibogaine Hydrochloride, Placebo, Microcrystalline cellulose | atai Therapeutics, Inc., MAC Clinical Research, ERT: Clinical Trial Technology Solutions, Hammersmith Medicines Research | Opiate Withdrawal Syndrome | 01/24 | 01/24 | | |
| Recruiting | 1/2 | 403 | US | FMC-376 | Frontier Medicines Corporation | Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer | 10/27 | 04/28 | | |
NCT05450549: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants |
|
|
| Completed | 1 | 47 | Europe | DNL919, Placebo | Denali Therapeutics Inc., Takeda | Healthy Participant | 06/23 | 06/23 | | |
NCT03832985: Pediatric Reporting of Adult-Onset Genomic Results |
|
|
| Completed | 1 | 427 | US | Receive an adult-onset result, Receive a pediatric-onset result, Control - No Result | Geisinger Clinic, National Human Genome Research Institute (NHGRI) | Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia | 10/24 | 10/24 | | |
MV371 LAI FiH, NCT06558643: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants |
|
|
| Recruiting | 1 | 24 | Europe | MMV371 LAI, Placebo for MMV371 | Medicines for Malaria Venture, Quotient Sciences, The Doctors Laboratory | Malaria,Falciparum | 03/25 | 03/25 | | |
NCT06639724: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer |
|
|
| Recruiting | 1 | 36 | US | Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) | University of California, San Diego, Rigel Pharmaceuticals | Pancreatic Ductal Adenocarcinoma (PDAC) | 06/27 | 12/28 | | |
NCT06586255: Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer |
|
|
| Recruiting | 1 | 10 | US | Concurrent Immunotherapy and Radiation Therapy | Abramson Cancer Center at Penn Medicine | Urothelial Carcinoma Bladder, Bladder Cancer | 04/27 | 04/27 | | |
| Recruiting | 1 | 108 | US | Psilocybin, Psilocybine, Psilocibin, Filament Health Psilocybin, PEX010, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS | University of Wisconsin, Madison, Tiny Blue Dot Foundation | Healthy, Psychedelic Experiences, Vagus Nerve Stimulation | 11/27 | 01/28 | | |
NCT06129084: A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing |
|
|
| Recruiting | N/A | 260 | Canada | FGFR Testing | Bernie Eigl, Vancouver Prostate Centre, Lady Davis Institute, Bladder Cancer Canada | Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma | 03/25 | 05/25 | | |
| Recruiting | N/A | 192 | RoW | Focused-PPC Care, Usual Care | University of Notre Dame, Savana Signatures, Indiana University School of Medicine | Postpartum Care | 01/23 | 06/23 | | |
| Recruiting | N/A | 400 | Europe, Canada, RoW | Pacing | Population Health Research Institute, Canadian Institutes of Health Research (CIHR) | Calcium Release Deficiency Syndrome (CRDS) | 12/25 | 03/26 | | |
| Completed | N/A | 23 | US | | Pennington Biomedical Research Center, National Institute of General Medical Sciences (NIGMS) | Hiv, Lung Injury | 08/23 | 12/23 | | |
| Recruiting | N/A | 190 | US | Customized Adherence Enhancement (CAE), Enhanced Treatment as Usual (eTAU) | Case Western Reserve University, National Institute of Mental Health (NIMH) | Bipolar Disorder | 11/25 | 05/26 | | |
TECHWISE, NCT06664944: Technology Exposure and Child Health: Wellness Impact and Social Effects: an Observational Product Registry Study |
|
|
| Recruiting | N/A | 1000 | US | | Aura | Mood, Depression Disorders, Anxiety Disorders, Sleep, Eating Disorders, Physical Activity, Loneliness, Stress | 12/25 | 12/25 | | |
| Recruiting | N/A | 500 | Canada | | Population Health Research Institute, Canadian Institutes of Health Research (CIHR) | Calcium Release Deficiency Syndrome | 12/50 | 12/50 | | |
NCT06812117: A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study) |
|
|
| Recruiting | N/A | 720 | RoW | No Drug | Daiichi Sankyo | Diabetic Peripheral Neuropathic Pain | 02/26 | 04/26 | | |
| Not yet recruiting | N/A | 20 | US | Freedom Pursuit Robotic Platform | Abramson Cancer Center at Penn Medicine | Brain Cancer | 02/27 | 02/27 | | |
RERUN, NCT06809764: Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC |
|
|
| Not yet recruiting | N/A | 150 | RoW | No drug | Daiichi Sankyo | Non-small Cell Lung Cancer | 02/27 | 02/27 | | |
NCT06659900: Community Vital Signs (CVS): an Integrated Community-Based Approach to Identify Undiagnosed Hypertension in Nigeria |
|
|
| Not yet recruiting | N/A | 24000 | RoW | CORE Plus (+), CORE | Oregon Health and Science University, University of Nigeria Nsukka | Hypertension | 06/27 | 06/27 | | |
| Active, not recruiting | N/A | 110 | US | Novel Communication Intervention, Enhanced Usual Care Parent Education | Indiana University, National Cancer Institute (NCI) | End of Life, Communication, Cancer Metastatic | 04/25 | 04/25 | | |
| Not yet recruiting | N/A | 190 | US | Smoking outcomes | University of Oklahoma | Cigarillo Flavor | 02/29 | 06/29 | | |
| Recruiting | N/A | 400 | Europe | ctDNA | Royal Marsden NHS Foundation Trust, Massachusetts General Hospital, Natera, Inc. | Breast Cancer | 12/25 | 12/28 | | |
NCT05568264: Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit |
|
|
| Recruiting | N/A | 192 | US | Physical Therapy intervention | Shirley Ryan AbilityLab, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University, Northwestern Medicine, University of Illinois at Chicago | Motor Delay, Premature Birth, Intraventricular Hemorrhage, Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia | 05/26 | 12/26 | | |
NCT01577251: The Radiation Oncology Registry and Biosample Repository |
|
|
| Recruiting | N/A | 8000 | US | | Abramson Cancer Center at Penn Medicine | Neoplasia | 12/30 | 12/30 | | |
| Aissa, Myriam Ait |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
| Chowdary, Pratima |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Terminated | 3 | 15 | RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 01/25 | 01/25 | | |
| Recruiting | 2 | 66 | Europe | nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV | University College, London | COVID | 04/21 | 04/21 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
|
|
| Active, not recruiting | 2 | 60 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 02/25 | | |
| Recruiting | 1/2 | 18 | Europe, US | AAV2/8-HLP-FVIII-V3 | University College, London, Medical Research Council | Hemophilia A | 01/29 | 12/29 | | |
| Terminated | N/A | 108 | Europe, Canada, US, RoW | No Intervention | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 11/24 | | |
| Recruiting | N/A | 10 | Europe | Liver biopsy | University College, London | Hemophilia B, Severe, Hemophilia A, Severe | 07/25 | 07/25 | | |
| Harber, Mark |
NCT04388930: The Microbiota in Kidney Donation and Transplantation |
|
|
| Recruiting | N/A | 130 | Europe | Pre-operative assessment - blood, urine, & faecal sample, Post-operative day 3 assessment - blood, urine, & faecal sample, Post-operative week 4-6 assessment - blood, urine, & faecal sample, Post-operative 3 month assessment - blood, urine, & faecal sample, Pre-operative 6 month assessment - blood, urine, & faecal sample, Post-operative month 12 recipient assessment - blood, urine, & faecal sample | Royal Free Hospital NHS Foundation Trust, University College, London | Kidney Diseases, Kidney Transplant Failure and Rejection, Urinary Tract Infections | 06/25 | 06/25 | | |
| Thorburn, Douglas |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Recruiting | 3 | 251 | Europe, Canada, Japan, US, RoW | Linerixibat | GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited | Cholestasis | 02/27 | 02/27 | | |
| Recruiting | 2 | 58 | Europe | Faecal Microbiota Transplant, FMT Placebo | University of Birmingham, PSC Support, Life Arc | Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases | 04/26 | 07/26 | | |
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd., ChemomAb Ltd | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
EMPHATIC, NCT06434493: Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 30 | NA | Proton Beam Therapy, Concurrent oral capecitabine chemotherapy, Cisplatin & Gemcitabine intravenous chemotherapy, Orthotropic Liver Transplant | The Christie NHS Foundation Trust, University College London Hospitals, University College, London, Royal Free Hospital NHS Foundation Trust | Cholangiocarcinoma | 06/28 | 06/29 | | |
| Ishii, Tomonori |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Phillips, Mark |
| Recruiting | 2 | 66 | Europe | nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV | University College, London | COVID | 04/21 | 04/21 | | |
